timothy sykes logo
Top Biotech Penny Stocks in Feb: The NVDA Partnership Edition Thumbnail
G Google News

Top Biotech Penny Stocks in Feb: The NVDA Partnership Edition

TIM SYKES•UPDATED FEB. 20, 2025, 5:52 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Biotech penny stocks are some of the most volatile plays in the market. These small companies focus on developing treatments and medical technologies, and their stock prices often skyrocket (or crash) based on clinical trial results, regulatory approvals, and industry news.

The potential for big moves is there, but so is the risk. Many of these companies rely on stock dilution to raise cash, which can sink share prices fast.

Here are three biotech penny stocks I’m watching this month:

  • Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) — The Weekend Winner Biotech Stock I Sold Too Soon
  • Firefly Neuroscience Inc. (NASDAQ: AIFF) — The NVIDIA Partnership Biotech Penny Stock
  • Kindly MD Inc. (NASDAQ: KDLY) — The Healthcare Penny Stock Spiker

Disclaimer: This is a watchlist, not a buy list. There’s no guarantee these stocks will present a solid trade opportunity. Stay patient and only trade setups that match your strategy.

Check out my complete biotech penny stock watchlist here!

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) — The Weekend Winner Biotech Stock I Sold Too Soon

Every Friday, I look for a specific weekend trading pattern. RXRX followed that pattern perfectly on February 14.

I bought shares late in the trading session and sold in after-hours for a quick profit. But if I had held through the weekend and sold Monday, my gains would have been even bigger.

  • Why traders are watching RXRX:
    • It followed my weekend trading pattern and still has strong momentum.
    • Biotech stocks are highly volatile right now, making it a prime watchlist candidate.
    • Holding its gains, which is key for multi-day runners.

This stock is still on my radar. If it sets up again, I’ll be ready.

Firefly Neuroscience Inc. (NASDAQ: AIFF) — The NVIDIA Partnership Biotech Penny Stock

Few catalysts have been as hot as NVIDIA partnerships. The market eats up any penny stock that announces a connection to NVIDIA—whether it’s a direct investment, a business collaboration, or even just incorporating NVIDIA technology.

AIFF took advantage of this trend. On February 11, the company announced it was accepted into an NVIDIA connect program.

Within three days, the stock price spiked 450%*.

  • Why traders are watching AIFF:
    • It has a low float (3.2 million shares), which fuels volatility.
    • NVIDIA-related penny stocks have a history of spiking.
    • Still on watch for potential follow-up bounces.

If another biotech stock announces an NVIDIA partnership, traders will be watching. AIFF wasn’t the first, and it won’t be the last.

More Breaking News

Kindly MD Inc. (NASDAQ: KDLY) — The Healthcare Penny Stock Spiker

KDLY spiked hard after announcing a new behavioral clinic at Ogden Regional Medical Center on February 12.

With a tiny float of 1.9 million shares, demand quickly outpaced supply, causing the stock to spike 260%* that day.

  • Why traders are watching KDLY:
    • Low float stocks move fast, and KDLY has proven it can spike.
    • The price action still fits my trading patterns.
    • Strong support at key technical levels, making it a potential setup.

Knowing where support and resistance levels are can help you plan better trades.

* Past performance doesn’t indicate future results.

Final Thoughts

  • RXRX followed my weekend pattern and could set up again.
  • AIFF is a low-float runner tied to NVIDIA, a proven hot catalyst.
  • KDLY spiked on healthcare expansion news and has strong technical levels.

This is a market tailor-made for traders who are prepared. Biotech penny stocks thrive on volatility, but it’s up to you to capitalize on it. Stick to your plan, manage your risk, and don’t let FOMO drive your decisions.

These opportunities are fast and unpredictable, but with the right strategy, you can make them work for you.

I recommend that you pay close attention to the first days of this possibly historic bull market.

If you want to know what I’m looking for—check out my free webinar here!

Which biotech penny stocks are you watching this month? Drop me a comment and let me know your game plan.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”